This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Asmann, Y. W. Articles by Vasmatzis, G. Search for Related Content PubMed PubMed Citation Articles by Asmann, Y. W. Articles by Vasmatzis, G.

Identification of Differentially Expressed Genes in Normal and Malignant Prostate by Electronic Profiling of Expressed Sequence Tags

Division of Experimental Pathology, Department of Laboratory Medicine and Pathology, and Mayo Cancer Center, Mayo Clinic and Foundation, Rochester, Minnesota, 55905

Differentially expressed genes between corresponding normal and cancertissue can advance our understanding of the molecular basis of malignancy and potentially serve as biomarkers or prognostic markers of malignancy. To identify differentially expressed genes in prostate cancer, we used a procedure combining electronic expression profiling of the prostate expressed sequence tag (EST) database and molecular biology techniques. A novel electronic expression-profiling algorithm was developed to search publicly available EST sequences for genes that show significant differential expression in prostate cancer compared with normal prostate tissue. Approximately 600 genes expressed in prostate were identified through adequate EST counts of ESTs for electronic profiling. Of these 600 genes, 9 showed statistically significant differences in their EST counts between cancer and normal prostate and were further analyzed. The predictions associated with electronic profiling were experimentally verified for two genes, cysteine-rich secretory protein 3 (CRISP-3) and deadenylating nuclease (DAN), using real-time reverse transcription-PCR with total RNA extracted from cells isolated by laser capture microdissection. In five of five Gleason score 6 cancer cases, CRISP-3 expression was increased >50 fold, whereas the expression of DAN was reduced by >80%.

This article has been cited by other articles:

				A. S. Bjartell, H. Al-Ahmadie, A. M. Serio, J. A. Eastham, S. E. Eggener, S. W. Fine, L. Udby, W. L. Gerald, A. J. Vickers, H. Lilja, et al. Association of Cysteine-Rich Secretory Protein 3 and {beta}-Microseminoprotein with Outcome after Radical Prostatectomy Clin. Cancer Res., July 15, 2007; 13(14): 4130 - 4138. [Abstract] [Full Text] [PDF]

				G. Vasmatzis, E. W. Klee, D. M. Kube, T. M. Therneau, and F. Kosari Quantitating tissue specificity of human genes to facilitate biomarker discovery Bioinformatics, June 1, 2007; 23(11): 1348 - 1355. [Abstract] [Full Text] [PDF]

				L. Udby, A. Bjartell, J. Malm, A. Egesten, A. Lundwall, J. B. Cowland, N. Borregaard, and L. Kjeldsen Characterization and Localization of Cysteine-Rich Secretory Protein 3 (CRISP-3) in the Human Male Reproductive Tract J Androl, May 1, 2005; 26(3): 333 - 342. [Abstract] [Full Text] [PDF]

				J. T. Posey, M. S. Soloway, S. Ekici, M. Sofer, F. Civantos, R. C. Duncan, and V. B. Lokeshwar Evaluation of the Prognostic Potential of Hyaluronic Acid and Hyaluronidase (HYAL1) for Prostate Cancer Cancer Res., May 15, 2003; 63(10): 2638 - 2644. [Abstract] [Full Text] [PDF]

				F. Kosari, Y. W. Asmann, J. C. Cheville, and G. Vasmatzis Cysteine-rich Secretory Protein-3: A Potential Biomarker for Prostate Cancer Cancer Epidemiol. Biomarkers Prev., November 1, 2002; 11(11): 1419 - 1426. [Abstract] [Full Text] [PDF]